These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 7974341

  • 1. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, Rumley A, Ludlam CA.
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G.
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [Abstract] [Full Text] [Related]

  • 11. Immunopurified clotting factor concentrates.
    Mariani G, Di Nucci GD, Arcieri P.
    Nouv Rev Fr Hematol (1978); 1994 Feb; 36 Suppl 1():S61-5. PubMed ID: 8177718
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM.
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract] [Full Text] [Related]

  • 15. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD.
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A, Laurian Y, Rothschild C, Navarro R, Guérois C, Gay V, Durin A, Peynet J, Sultan Y.
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [Abstract] [Full Text] [Related]

  • 19. Development of anaphylactic shock in haemophilia B patients with inhibitors.
    Warrier I, Lusher JM.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.